Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1475
Shown on this page
12
Current sort
Recently updated
Campus scope
Massachusetts General Hospital, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Massachusetts General Hospital, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 901–912 of 1,475 matching trials with a site at Massachusetts General Hospital, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Conditions
B-Cell Malignancies
Interventions
Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib, parsaclisib + ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 20 more
Recruiting Phase 2 Interventional

Tofersen in Non-SOD1 ALS

NCT07294144
Status at this site: Recruiting
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Tofersen
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • St Louis, Missouri
Recruiting No phase listed Observational

TSC Biosample Repository and Natural History Database

NCT05676099
Status at this site: Recruiting
Conditions
Tuberous Sclerosis, Lymphangioleiomyomatosis
Interventions
Phlebotomy, Buccal (cheek) swab, Genetic Testing, Tissue donation after routine clinical procedure
Procedure · Genetic · Other
Lead sponsor
National Tuberous Sclerosis Association
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2050
U.S. locations
24
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 19 more
Active, not recruiting Phase 3 Interventional Results available

Troriluzole in Adult Participants With Spinocerebellar Ataxia

NCT03701399
Site status not listed — check the official record
Conditions
Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10
Interventions
troriluzole, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 16 more
Active, not recruiting Phase 2 Interventional Results available

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

NCT02425904
Site status not listed — check the official record
Conditions
Langerhans Cell Histiocytosis
Interventions
Clofarabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more
Conditions
Colorectal Cancer Prevention, Colorectal Adenoma
Interventions
Increased Plant-Based Diet and Decreased Animal-Based Diet
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Aortic Stenosis
Interventions
Pelacarsen (TQJ230) 80mg, Matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 80 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
35
States / cities
Huntsville, Alabama • Beverly Hills, California • Covina, California + 26 more
Recruiting Phase 1 Interventional

A Study of LY4175408 in Participants With Advanced Cancer

NCT07046923
Status at this site: Recruiting
Conditions
Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis, Triple Negative Breast Cancer
Interventions
LY4175408, Pembrolizumab, Carboplatin, Cisplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
15
States / cities
Stanford, California • Orlando, Florida • Sarasota, Florida + 11 more
Active, not recruiting Not applicable Interventional

The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)

NCT05820087
Site status not listed — check the official record
Conditions
Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor, Tumor, Benign
Interventions
HistoSonics Edison System
Device
Lead sponsor
HistoSonics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
15
States / cities
Los Angeles, California • Mission Viejo, California • New Haven, Connecticut + 10 more
Conditions
Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
Interventions
Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide, Bortezomib for Injection, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
3
States / cities
Boston, Massachusetts
Active, not recruiting Phase 1 Interventional

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

NCT04277637
Site status not listed — check the official record
Conditions
Mature B-Cell Malignancies
Interventions
Sonrotoclax, Zanubrutinib, Obinutuzumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 9 more
Recruiting Not applicable Interventional

Well-being in IBS: Strengths and Happiness (WISH) 2.0

NCT06866106
Status at this site: Recruiting
Conditions
Irritable Bowel Syndrome
Interventions
Positive Psychology (PP) Intervention, Educational Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts

About this Massachusetts General Hospital institution page

What this page lists
ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Massachusetts General Hospital at any site, browse by condition, or browse by U.S. city.